Despite recent failures, a flurry of activity in biotech and pharma is raising hopes that an effective drug for this fatal lung disease is on the way. Ken Garber investigates.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Noble, P.W. et al. Lancet 377, 1760–1769 (2011).
Raghu, G. et al. Am. J. Respir. Crit. Care Med. 183, 788–824 (2011).
Barry-Hamilton, V. et al. Nat. Med. 16, 1009–1017 (2010).
Tager, A.M. et al. Nat. Med. 14, 45–54 (2008).
Richeldi, L. et al. N. Engl. J. Med. 365, 1079–1087 (2011).
Maher, T.M. Eur. Respir. Rev. 22, 148–152 (2013).
Idiopathic Pulmonary Fibrosis Clinical Research Network. N. Engl. J. Med. 366, 1968–1977 (2012).
Van Den Blink, B. et al. American Thoracic Society meeting abstract A5707 (2013).
Rights and permissions
About this article
Cite this article
At the frontiers of lung fibrosis therapy. Nat Biotechnol 31, 781–783 (2013). https://doi.org/10.1038/nbt.2687
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt.2687
This article is cited by
-
The multifaceted roles of FOXM1 in pulmonary disease
Cell Communication and Signaling (2019)
-
IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts
Respiratory Research (2018)
-
Landmark approvals in idiopathic pulmonary fibrosis
Nature Biotechnology (2014)
